Extracorporeal membrane oxygenation in life-threatening asthma unresponsive to mechanical ventilation: a comparison of patient demographics and outcomes between a large London-based intensive care unit and an international registry

Authors: Kritchai Vutipongsatorn, A Eri Fujitake A and Suveer Singh B

Introduction
According to the British Thoracic Society (BTS) guidelines, extracorporeal membrane oxygenation (ECMO) may be considered in near-fatal asthma exacerbations refractory to conventional ventilator treatment. However, there is currently no clear criteria for accepting such patients for ECMO treatment. The comparison of local data to an internationally established database would lead to a better insight into optimal criteria for the commencement of ECMO treatment.

Methods
Medical records of asthmatic patients who were admitted to Royal Brompton Hospital (RBH) for ECMO from 2012 to 2018 were reviewed. Parameters such as pre- and post-ECMO blood gases, ventilator settings and outcomes were calculated and compared with the Extracorporeal Life Support Organization (ELSO) registry, an international database for ECMO from 1992 to 2016 (n=272).

Results and discussion
Ten patients (38.4 ± 13.6 years) were identified. Sixty per cent were known asthmatics, and 40% had previous hospital admissions for asthma. Eighty per cent had an infective trigger. The mean duration on ECMO and stay on intensive treatment unit (ITU) were 6.7 ± 2.9 days and 11.9 ± 5.3 days, respectively. Compared with the ELSO registry, there were no significant differences in patient demographics. Prior to ECMO, RBH patients were significantly more hypercapnic (16.0 vs 10.7 kPa, p=0.014), and were on a significantly less aggressive ventilator setting with regards to FiO2 (57.1% vs 81.2%, p=0.002) and positive end-expiratory pressure (PEEP) (4.3 vs 8.3 kPa, p=0.043). However, there were no significant differences in survival (100% vs 83.5%, p=0.363) or duration on ECMO (6.7 vs 7.4 days, p=0.785). The pre-ECMO blood gas and ventilation settings could indicate a higher threshold for commencing ECMO in the RBH cohort, or the result of less aggressive ventilation settings prior to starting ECMO. However, this had no impact on survival and duration on ECMO.

Conclusion
Despite similar outcomes, there are significant differences in the RBH cohort with regards to the pre-ECMO ventilation settings and blood gases. As recommended by the BTS, further research of a bigger sample size is required to improve understanding of treatment-refractory fatal asthma.

Conflict of interest statement
None declared.

References

Authors: A Imperial College London, UK; B Royal Brompton Hospital, London, UK